For Debate: Will we ever know when to treat HIV infection?

BMJ

Volumn 313, Issue 7057, 1996, Pages 608-610

  Phillips, Andrew N ^a   Smith, George Davey ^b   Johnson, Margaret A ^a  

^a ROYAL FREE HOSPITAL   (United Kingdom)

^b UNIVERSITY OF BRISTOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; NUCLEOSIDE ANALOG; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ANTIMICROBIAL THERAPY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE DEFICIENCY; PRIORITY JOURNAL; SHORT SURVEY; SURVIVAL; TREATMENT PLANNING;

ANTIVIRAL AGENTS; HIV INFECTIONS; HUMANS; RANDOMIZED CONTROLLED TRIALS; REVERSE TRANSCRIPTASE INHIBITORS; TIME FACTORS; TREATMENT OUTCOME; ZIDOVUDINE;

EID: 9544221666     PISSN: 09598138     EISSN: 14685833     Source Type: Journal    
DOI: 10.1136/bmj.313.7057.608     Document Type: Article

References (25)

1. Fischl MA, Richman DD, Grieco MH, et al. The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. N Engl J Med 1987; 317: 185-91.
2. Bartlett JG. Zidovudine now or later? N Engl J Med 1993; 329: 351-2.
3. James JS AZT, early intervention, and the Concorde controversy. AIDS Treatment News 1993;No 173.
4. Gazzard BG. After Concorde. BMJ 1993; 306: 1016-7.
5. Anonymous. Zidovudine for symptomless HIV infection. Lancet 1990; 335: 821-2.
6. Swart AM, Weller I, Darbyshire JH. Early HIV infection: to treat or not to treat. BMJ 1990; 301: 825-6.
7. Pinching AJ. Zidovudine in asymptomatic HIV infection: knowledge and uncertainty. Int J STD AIDS 1991; 2: 157-61.
8. Corey L, Fleming TR. Treatment of HIV Infection - progress in perspective. N Engl J Med 1992; 326: 484-5.
9. Ho DD. Time to hit HIV, early and hard. N Engl J Med 1995; 333: 450-1.
10. Wei X, Ghosh SK, Taylor ME, Johnson VA, Emini EA, Deutsch, et al. Viral dynamics in HIV-1 infection. Nature 1995; 373: 117-22.
11. Ho DD, Neumann AU, Perelson AS, Chen W, Leonard J, Markowitz M. Rapid turnover of plasma virons and CD4 lymphocytes in HIV-1 infection. Nature 1995; 373: 123-6.
12. Pantaleo G, Graziosi C, Demarest JF, Butini L, Montrani M, Fox CH, et al. HIV infection is active and progressive in lymphoid tissue during the clinically latent stage of disease. Nature 1993; 362: 355-8.
13. Pezzotti P, Phillips AN, Dorrucci M, Cozzi Lepri A, Galai N, Vlahov D, et al and the Italian Seroconversion Study. HIV exposure category and age in the progression to AIDS in a longitudinal study of 1199 individuals with known seroconversion dates. BMJ 1996; 312 press.
14. Phillips AN, Sabin CA, Elford J, Bofill M, Janossy G, Lee CA. Use of CD4 lymphocyte count to predict long term survival free of AIDS after HIV infection. BMJ 1994; 309: 309-14.
15. Lenderking WR, Gelber RD, Cotton DJ, Cole BF, Goldhirsch A, Volberding PA, et al. Evaluation of the quality of life associated with zidovudine treatment in asymptomatic HIV infection. N Engl J Med 1994; 330: 738-43.
16. Egger M, Neaton JD, Phillips AN, Davey Smith G. Concorde trial of immediate versus deferred zidovudine. Lancet 1994; 343: 1355.
17. Concorde Coordinating Committee. Concorde: MRC/ANRS randomised double-blind controlled trial of immediate and deferred zidovudine in symptom-free HIV infection. Lancet 1994; 343: 871-81.
18. Volberding PA, Lagakos SW, Koch MA, Pettinelli C, Myers MW, Booth DK, et al. Zidovudine in asymptomatic HIV-1 infection. N Engl J Med 1990; 322: 941-9.
19. Volberding PA, Lagakos SW, Grimes JM, Stein DS, Rooney J, Meng TC, et al. A comparison of immediate with deferred zidovudine therapy for asymptomatic HIV-infected adults with CD4 cell counts of 500 or more per cubic millimeter. N Engl J Med 1995; 333: 401-7.
20. Hamilton JD, Hartigan PM, Simberkoff MS, Day PL, Diamond GR, Dickinson GM, et al. A controlled trial of early versus late treatment with zido vudine in symptomatic HIV infection. Results of the Veterans Affairs Cooperative Study. N Engl J Med 1993; 326: 437-43.
21. Cooper DA, Gatell JM, Kroon S, Clumeck N, Millard J, Goebel FD, et al. Zidovudine in persons with asymptomatic HIV infection and CD4+ cell counts greater than 400 per cubic millimeter. N Engl J Med 1993; 329: 297-303.
22. Mulder JW, Cooper DA, Mathiesen L, Sandstrom E, Clumeck N, Gatell JM, et al. Zidovudine twice daily in asymptomatic subjects with HIV infection and a high risk of progression to AIDS: a randomised, double-blind placebo-controlled study. AIDS 1994; 8: 313-21.
23. Fischl MA, Richman DD, Hansen N, Collier AC, Carey JT, Para MF, et al. The safety and efficacy of zidovudine (AZT) in the treatment of subjects with mildly symptomatic HIV-1 infection. Ann Intern Med 1990; 112: 727-37.
24. Pinching AJ. Managing HIV disease after Delta. BMJ 1996; 312: 521-2.
25. Volberding PA, Lagakos SW, Grimes JM, Stein DS, Balfour HH, Reichman RC, et al. The duration of zidovudine benefit in persons with asymptomatic HIV infection. Prolonged evaluation of protocol 019 of the AIDS Clinical Trials Group. JAMA 1994; 272: 437-42.